Fierce Medtech Names CVRx as One of its “Fierce 15” Companies MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announces it has been selected...

CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that it is expanding...

CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status MINNEAPOLIS, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that the Centers for...

CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) -- CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s...